Leading Companies Propelling Growth and Innovation in the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market

The cell and gene therapy contract development and manufacturing organization (CDMO) market is on track for remarkable expansion over the coming years. Driven by technological advances and increasing demand for specialized manufacturing services, this sector is positioned to make a significant impact in the biopharmaceutical landscape by 2030.

Projected Market Growth and Size of the Cell and Gene Therapy CDMO Market
The cell and gene therapy CDMO market is anticipated to grow substantially, reaching a valuation of $21.35 billion by 2030. This represents a powerful compound annual growth rate (CAGR) of 24.6%. Several factors contribute to this rapid growth, including the mounting commercialization of gene-modified therapies, a rising need for adaptable manufacturing capacities, broadening global CDMO partnerships, increased funding for cell therapy development, and a surge in regulatory approvals for advanced therapeutic products. Key trends influencing this market include the expansion of comprehensive end-to-end CDMO services, the growing requirement for commercial-scale manufacturing support, wider adoption of cutting-edge gene editing technologies, a sharp focus on accelerating development timelines, and stronger integration of regulatory assistance services.

Download a free sample of the cell and gene therapy contract development and manufacturing organization (cdmo) market report:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Drivers Fueling Growth in the Cell and Gene Therapy CDMO Sector
The expanding commercialization of gene-modified therapies is a major force propelling the market forward. As more gene and cell therapies move from clinical trials to commercial production, the need for specialized contract development and manufacturing services surges accordingly.
Additionally, the demand for flexible and scalable manufacturing capabilities is rising. This flexibility allows companies to efficiently handle fluctuating production volumes while complying with strict regulatory standards, further boosting the appeal of CDMO partnerships globally.

Prominent Players Steering the Cell and Gene Therapy CDMO Industry
The market landscape features several influential companies, including Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, and Porton Advanced Solutions Ltd.

The cell and gene therapy contract development and manufacturing organization (CDMO) market is on track for remarkable expansion over the coming years. Driven by technological advances and increasing demand for specialized manufacturing services, this sector is positioned to make a significant impact in the biopharmaceutical landscape by 2030.

Projected Market Growth and Size of the Cell and Gene Therapy CDMO Market
The cell and gene therapy CDMO market is anticipated to grow substantially, reaching a valuation of $21.35 billion by 2030. This represents a powerful compound annual growth rate (CAGR) of 24.6%. Several factors contribute to this rapid growth, including the mounting commercialization of gene-modified therapies, a rising need for adaptable manufacturing capacities, broadening global CDMO partnerships, increased funding for cell therapy development, and a surge in regulatory approvals for advanced therapeutic products. Key trends influencing this market include the expansion of comprehensive end-to-end CDMO services, the growing requirement for commercial-scale manufacturing support, wider adoption of cutting-edge gene editing technologies, a sharp focus on accelerating development timelines, and stronger integration of regulatory assistance services.

Download a free sample of the cell and gene therapy contract development and manufacturing organization (cdmo) market report:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Key Drivers Fueling Growth in the Cell and Gene Therapy CDMO Sector
The expanding commercialization of gene-modified therapies is a major force propelling the market forward. As more gene and cell therapies move from clinical trials to commercial production, the need for specialized contract development and manufacturing services surges accordingly.
Additionally, the demand for flexible and scalable manufacturing capabilities is rising. This flexibility allows companies to efficiently handle fluctuating production volumes while complying with strict regulatory standards, further boosting the appeal of CDMO partnerships globally.

Prominent Players Steering the Cell and Gene Therapy CDMO Industry
The market landscape features several influential companies, including Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, and Porton Advanced Solutions Ltd.

Significant Acquisition Highlighting Market Expansion
In November 2023, Ajinomoto Co. Inc., a biotechnology and food corporation based in Japan, acquired Forge Biologics for $620 million. This strategic move strengthens Ajinomoto's global manufacturing capabilities in adeno-associated virus (AAV) and plasmid gene therapy production, enhancing its existing contract development and manufacturing service offerings. Forge Biologics is a US-based gene therapy CDMO and clinical-stage therapeutics company, making this acquisition a notable boost to Ajinomoto's position in the market.

Emerging Trends Shaping the Cell and Gene Therapy CDMO Market
Leading companies in this space are focusing on technological innovation to improve overall manufacturing efficiency. For example, new developments in polishing equipment for dental applications, like the DLyte Mini introduced by Spain's GPAinnova in March 2023, highlight the trend toward precision and automation in biotech-related manufacturing processes. This compact polishing machine uses dry polishing technology, which eliminates water use and enhances workflow cleanliness and speed.
The DLyte Mini employs electrochemical polishing to deliver high-quality finishes on materials such as titanium, zirconia, and cobalt-chromium, making it ideal for laboratories with limited space while maintaining professional standards. Innovations like these reflect broader efforts to optimize manufacturing processes in related biotech fields.

Detailed Segmentation of the Cell and Gene Therapy CDMO Market
This market is segmented based on product type, clinical phase, and indication. The product categories include Gene Therapy, Gene-Modified Cell Therapy, and Cell Therapy. Clinical phases covered are Phase 1, Phase 2, and Phase 3. Indications span Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, and other medical conditions.

Further subdivisions specify:
- Gene Therapy types: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, and Plasmid DNA-Based Gene Therapy
- Gene-Modified Cell Therapy types: CAR-T Cell Therapy, TCR-T Cell Therapy, and NK Cell Therapy
- Cell Therapy types: Stem Cell Therapy, Progenitor Cell Therapy, and Immune Cell Therapy

This detailed breakdown offers a comprehensive overview of the market's diverse applications and specialized focus areas.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.